{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T20:47:25Z","timestamp":1788554845392,"version":"build-2803163510"},"reference-count":153,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,4,13]],"date-time":"2024-04-13T00:00:00Z","timestamp":1712966400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","thrombosisresearch.com","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Thrombosis Research"],"published-print":{"date-parts":[[2024,6]]},"DOI":"10.1016\/j.thromres.2024.04.009","type":"journal-article","created":{"date-parts":[[2024,4,13]],"date-time":"2024-04-13T21:42:43Z","timestamp":1713044563000},"page":"1-10","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":30,"special_numbering":"C","title":["Oral anticoagulant therapy in older adults"],"prefix":"10.1016","volume":"238","author":[{"given":"J.","family":"Stuby","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Haschke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Tritschler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Aujesky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.thromres.2024.04.009_bb0005","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1111\/jcpt.13508","article-title":"Prevalence and the factors associated with oral anticoagulant use among nursing home residents","volume":"46","author":"Chen","year":"2021","journal-title":"J. Clin. Pharm. Ther."},{"issue":"5","key":"10.1016\/j.thromres.2024.04.009_bb0010","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/j.amjmed.2019.09.026","article-title":"Oral anticoagulation in oatients in the emergency department: high rates of off-label doses, no difference in bleeding rates","volume":"133","author":"Eschler","year":"2020","journal-title":"American Journal of Medicine."},{"issue":"3","key":"10.1016\/j.thromres.2024.04.009_bb0015","first-page":"179","article-title":"Predisposing factors for atrial fibrillation in the elderly","volume":"14","author":"Wasmer","year":"2017","journal-title":"J. Geriatr. Cardiol."},{"key":"10.1016\/j.thromres.2024.04.009_bb0020","doi-asserted-by":"crossref","unstructured":"Akrivou D, Perlepe G, Kirgou P, Gourgoulianis KI, Malli F. Pathophysiological Aspects of Aging in Venous Thromboembolism: An Update. Medicina (Kaunas). 2022;vol. 58(8).","DOI":"10.3390\/medicina58081078"},{"issue":"8","key":"10.1016\/j.thromres.2024.04.009_bb0025","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1093\/eurheartj\/ehi825","article-title":"Prevalence, incidence and lifetime risk of atrial fibrillation: the Rotterdam study","volume":"27","author":"Heeringa","year":"2006","journal-title":"Eur. Heart J."},{"issue":"18","key":"10.1016\/j.thromres.2024.04.009_bb0030","doi-asserted-by":"crossref","first-page":"2370","DOI":"10.1001\/jama.285.18.2370","article-title":"Prevalence of diagnosed atrial aibrillation in adults national implications for rhythm management and stroke prevention: the anticoagulation and risk factors in atrial fibrillation (ATRIA) study","volume":"285","author":"Go","year":"2001","journal-title":"JAMA"},{"key":"10.1016\/j.thromres.2024.04.009_bb0035","article-title":"Age-dependent risk for thromboembolism in atrial fibrillation: the Fushimi AF registry","volume":"41","author":"Esato","year":"2022","journal-title":"International Journal of Cardiology: Heart & Vasculature."},{"issue":"8","key":"10.1016\/j.thromres.2024.04.009_bb0040","first-page":"1046","article-title":"Venous thromboembolism in very elderly patients: findings from a prospective registry (RIETE)","volume":"91","author":"Lopez-Jimenez","year":"2006","journal-title":"Haematologica"},{"issue":"5","key":"10.1016\/j.thromres.2024.04.009_bb0045","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1161\/CIRCEP.112.972869","article-title":"Assessing the risk of bleeding in patients with atrial fibrillation: the loire valley atrial fibrillation project","volume":"5","author":"Lip","year":"2012","journal-title":"Circ. Arrhythm. Electrophysiol."},{"issue":"8","key":"10.1016\/j.thromres.2024.04.009_bb0050","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1111\/j.1532-5415.2006.00828.x","article-title":"Age and the risk of warfarin-associated hemorrhage: the anticoagulation and risk factors in atrial fibrillation study","volume":"54","author":"Fang","year":"2006","journal-title":"J. Am. Geriatr. Soc."},{"issue":"10","key":"10.1016\/j.thromres.2024.04.009_bb0055","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.7326\/M21-1094","article-title":"Long-term risk for major bleeding during extended oral anticoagulant therapy for first unprovoked venous thromboembolism\u202f: a systematic review and meta-analysis","volume":"174","author":"Khan","year":"2021","journal-title":"Ann. Intern. Med."},{"issue":"11","key":"10.1016\/j.thromres.2024.04.009_bb0060","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2022.42964","article-title":"Trends in use of oral anticoagulants in older adults with newly diagnosed atrial fibrillation, 2010-2020","volume":"5","author":"Ko","year":"2022","journal-title":"JAMA Netw. Open"},{"issue":"12","key":"10.1016\/j.thromres.2024.04.009_bb0065","doi-asserted-by":"crossref","DOI":"10.1093\/ageing\/afac252","article-title":"Prevalence and outcomes of atrial fibrillation in older people living in care homes in wales: a routine data linkage study 2003\u20132018","volume":"51","author":"Ritchie","year":"2022","journal-title":"Age Ageing"},{"key":"10.1016\/j.thromres.2024.04.009_bb0070","doi-asserted-by":"crossref","first-page":"2363","DOI":"10.1182\/blood-2023-172922","article-title":"Oral anticoagulant (OAC) use among Medicare patients newly diagnosed with venous thromboembolism (VTE): factors associated with treatment status","volume":"142","author":"Coons","year":"2023","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.thromres.2024.04.009_bb0075","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1016\/S0531-5565(03)00133-5","article-title":"When drug therapy gets old: pharmacokinetics and pharmacodynamics in the elderly","volume":"38","author":"Turnheim","year":"2003","journal-title":"Exp. Gerontol."},{"issue":"4","key":"10.1016\/j.thromres.2024.04.009_bb0080","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1111\/jgs.16992","article-title":"Muscle mass and direct oral anticoagulant activity in older adults with atrial fibrillation","volume":"69","author":"Bendayan","year":"2021","journal-title":"J. Am. Geriatr. Soc."},{"key":"10.1016\/j.thromres.2024.04.009_bb0085","unstructured":"Bristol-Myers-Squibb-Canada. Apixaban summary of product characteristics [Available from: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/eliquis-epar-product-information_en.pdf."},{"key":"10.1016\/j.thromres.2024.04.009_bb0090","series-title":"Effect of Famotidine on the Pharmacokinetics of Apixaban, an Oral Direct Factor Xa Inhibitor","first-page":"59","author":"Upreti","year":"2013"},{"key":"10.1016\/j.thromres.2024.04.009_bb0095","unstructured":"Daiichi-Sankyo. Edoxaban summary of product characteristics [Available from: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/lixiana-epar-product-information_en.pdf."},{"issue":"5","key":"10.1016\/j.thromres.2024.04.009_bb0100","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.116.003432","article-title":"Efficacy and safety of edoxaban in elderly patients with atrial fibrillation in the ENGAGE AF-TIMI 48 trial","volume":"5","author":"Kato","year":"2016","journal-title":"J. Am. Heart Assoc."},{"key":"10.1016\/j.thromres.2024.04.009_bb0105","unstructured":"Bayer. Rivaroxaban summary of product characteristics [Available from: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/xarelto-epar-product-information_en.pdf."},{"issue":"2","key":"10.1016\/j.thromres.2024.04.009_bb0110","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1177\/0091270006296058","article-title":"Body weight has limited influence on the safety, tolerability, pharmacokinetics, or pharmacodynamics of rivaroxaban in healthy subjects","volume":"47","author":"Kubitza","year":"2007","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.thromres.2024.04.009_bb0115","unstructured":"Boehringer-Ingelheim. Dabigatran summary of product characteristics [Available from: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/pradaxa-epar-product-information_en.pdf."},{"issue":"04","key":"10.1016\/j.thromres.2024.04.009_bb0120","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1160\/TH11-09-0656","article-title":"A combined pharmacometric analysis of dabigatran etexilate in healthy volunteers and patients with atrial fibrillation or undergoing orthopaedic surgery","volume":"107","author":"Dansirikul","year":"2012","journal-title":"Thromb. Haemost."},{"issue":"8","key":"10.1016\/j.thromres.2024.04.009_bb0125","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.1253\/circj.CJ-11-1140","article-title":"Randomized, multicenter, warfarin-controlled phase II study of edoxaban in japanese patients with non-valvular atrial fibrillation","volume":"76","author":"Yamashita","year":"2012","journal-title":"Circ. J."},{"issue":"1","key":"10.1016\/j.thromres.2024.04.009_bb0130","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1111\/j.1365-2125.2011.04051.x","article-title":"The population pharmacokinetics of R- and S-warfarin: effect of genetic and clinical factors","volume":"73","author":"Lane","year":"2012","journal-title":"Br. J. Clin. Pharmacol."},{"issue":"6","key":"10.1016\/j.thromres.2024.04.009_bb0135","first-page":"529","article-title":"Treatment of venous thromboembolism in elderly patients in the era of direct oral anticoagulants","volume":"130","author":"Tritschler","year":"2020","journal-title":"Polish Archives of Internal Medicine."},{"key":"10.1016\/j.thromres.2024.04.009_bb0140","doi-asserted-by":"crossref","unstructured":"Ansell J, Hirsh J, Hylek E, Jacobson A, Crowther M, Palareti G. Pharmacology and management of the vitamin K antagonists: American college of chest physicians evidence-based clinical practice guidelines (8th edition). Chest. 2008;133(6 Suppl):160s\u201398s.","DOI":"10.1378\/chest.08-0670"},{"issue":"3","key":"10.1016\/j.thromres.2024.04.009_bb0145","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1007\/s40262-023-01222-w","article-title":"Insights into the pharmacokinetics and pharmacodynamics of direct oral anticoagulants in older adults with atrial fibrillation: a structured narrative review","volume":"62","author":"Edwina","year":"2023","journal-title":"Clin. Pharmacokinet."},{"issue":"1","key":"10.1016\/j.thromres.2024.04.009_bb0150","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1046\/j.1365-2125.2003.02007.x","article-title":"Age-related changes in pharmacokinetics and pharmacodynamics: basic principles and practical applications","volume":"57","author":"Mangoni","year":"2004","journal-title":"Br. J. Clin. Pharmacol."},{"issue":"4","key":"10.1016\/j.thromres.2024.04.009_bb0155","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1007\/s40262-013-0034-0","article-title":"Anticoagulant therapy with the oral direct factor Xa inhibitors rivaroxaban, apixaban and edoxaban and the thrombin inhibitor dabigatran etexilate in patients with hepatic impairment","volume":"52","author":"Graff","year":"2013","journal-title":"Clin. Pharmacokinet."},{"issue":"5","key":"10.1016\/j.thromres.2024.04.009_bb0160","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1111\/j.1365-2125.2012.04259.x","article-title":"Influence of adult age on the total and free clearance and protein binding of (R)- and (S)-warfarin","volume":"74","author":"Jensen","year":"2012","journal-title":"Br. J. Clin. Pharmacol."},{"issue":"9836","key":"10.1016\/j.thromres.2024.04.009_bb0165","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/S0140-6736(12)60240-2","article-title":"Epidemiology of multimorbidity and implications for health care, research, and medical education: a cross-sectional study","volume":"380","author":"Barnett","year":"2012","journal-title":"The Lancet."},{"issue":"1","key":"10.1016\/j.thromres.2024.04.009_bb0170","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1186\/s12877-022-03279-x","article-title":"Prevalence and factors associated with polypharmacy: a systematic review and meta-analysis","volume":"22","author":"Delara","year":"2022","journal-title":"BMC Geriatr."},{"issue":"6","key":"10.1016\/j.thromres.2024.04.009_bb0175","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1007\/s40262-014-0228-0","article-title":"Effects of age and sex on the single-dose pharmacokinetics and pharmacodynamics of apixaban","volume":"54","author":"Frost","year":"2015","journal-title":"Clin. Pharmacokinet."},{"issue":"Suppl. 1","key":"10.1016\/j.thromres.2024.04.009_bb0180","doi-asserted-by":"crossref","first-page":"9s","DOI":"10.1177\/1076029609343004","article-title":"Pharmacology, pharmacokinetics, and pharmacodynamics of dabigatran etexilate, an oral direct thrombin inhibitor","volume":"15","author":"Stangier","year":"2009","journal-title":"Clin. Appl. Thromb. Hemost."},{"issue":"6","key":"10.1016\/j.thromres.2024.04.009_bb0185","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1007\/s40262-015-0342-7","article-title":"Pharmacokinetics and pharmacodynamics of edoxaban, a non-vitamin K antagonist oral anticoagulant that inhibits clotting factor Xa","volume":"55","author":"Parasrampuria","year":"2016","journal-title":"Clin. Pharmacokinet."},{"issue":"4","key":"10.1016\/j.thromres.2024.04.009_bb0190","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.jacc.2013.07.104","article-title":"The effect of dabigatran plasma concentrations and patient characteristics on the frequency of ischemic stroke and major bleeding in atrial fibrillation patients: the RE-LY trial (randomized evaluation of long-term anticoagulation therapy)","volume":"63","author":"Reilly","year":"2014","journal-title":"J. Am. Coll. Cardiol."},{"issue":"3","key":"10.1016\/j.thromres.2024.04.009_bb0195","first-page":"203","article-title":"The influence of age, liver size and enantiomer concentrations on warfarin requirements","volume":"40","author":"Wynne","year":"1995","journal-title":"Br. J. Clin. Pharmacol."},{"issue":"6","key":"10.1016\/j.thromres.2024.04.009_bb0200","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1002\/phar.2089","article-title":"Influence of age on warfarin dose, anticoagulation control, and risk of hemorrhage","volume":"38","author":"Shendre","year":"2018","journal-title":"Pharmacotherapy"},{"issue":"6","key":"10.1016\/j.thromres.2024.04.009_bb0205","doi-asserted-by":"crossref","first-page":"2049","DOI":"10.1378\/chest.127.6.2049","article-title":"Warfarin maintenance dosing patterns in clinical practice: implications for safer anticoagulation in the elderly population","volume":"127","author":"Garcia","year":"2005","journal-title":"Chest"},{"issue":"7","key":"10.1016\/j.thromres.2024.04.009_bb0210","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1212\/WNL.55.7.947","article-title":"Warfarin-associated hemorrhage and cerebral amyloid angiopathy: a genetic and pathologic study","volume":"55","author":"Rosand","year":"2000","journal-title":"Neurology"},{"issue":"10","key":"10.1016\/j.thromres.2024.04.009_bb0215","doi-asserted-by":"crossref","first-page":"2140","DOI":"10.3748\/wjg.v9.i10.2140","article-title":"Pathophysiological aspects of diverticular disease of colon and role of large bowel motility","volume":"9","author":"Bassotti","year":"2003","journal-title":"World J. Gastroenterol."},{"issue":"21","key":"10.1016\/j.thromres.2024.04.009_bb0220","doi-asserted-by":"crossref","first-page":"6364","DOI":"10.3748\/wjg.v20.i21.6364","article-title":"Helicobacter pylori infection in older people","volume":"20","author":"Pilotto","year":"2014","journal-title":"World J. Gastroenterol."},{"issue":"5","key":"10.1016\/j.thromres.2024.04.009_bb0225","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1093\/eurheartj\/ehaa612","volume":"42","author":"Hindricks","year":"2020","journal-title":"Eur. Heart J."},{"issue":"19","key":"10.1016\/j.thromres.2024.04.009_bb0230","doi-asserted-by":"crossref","first-page":"4693","DOI":"10.1182\/bloodadvances.2020001830","article-title":"American society of hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism","volume":"4","author":"Ortel","year":"2020","journal-title":"Blood Adv."},{"issue":"6","key":"10.1016\/j.thromres.2024.04.009_bb0235","doi-asserted-by":"crossref","first-page":"e545","DOI":"10.1016\/j.chest.2021.07.055","article-title":"Antithrombotic therapy for VTE disease: second update of the CHEST guideline and expert panel report","volume":"160","author":"Stevens","year":"2021","journal-title":"Chest"},{"issue":"9","key":"10.1016\/j.thromres.2024.04.009_bb0240","first-page":"4471","article-title":"Bleeding in patients receiving vitamin K antagonists who would have been excluded from trials on which the indication for anticoagulation was based","volume":"111","author":"Levi","year":"2008","journal-title":"Blood, The Journal of the American Society of Hematology."},{"issue":"4","key":"10.1016\/j.thromres.2024.04.009_bb0245","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1055\/s-0042-1760365","article-title":"Bleeding risk in elderly patients with venous thromboembolismwho would have been excluded from anticoagulation trials","volume":"123","author":"Schenker","year":"2023","journal-title":"Thromb. Haemost."},{"issue":"6","key":"10.1016\/j.thromres.2024.04.009_bb0250","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2012-001768","article-title":"Representativeness of the dabigatran, apixaban and rivaroxaban clinical trial populations to real-world atrial fibrillation patients in the United Kingdom: a cross-sectional analysis using the general practice research database","volume":"2","author":"Lee","year":"2012","journal-title":"BMJ Open"},{"issue":"9921","key":"10.1016\/j.thromres.2024.04.009_bb0255","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1016\/S0140-6736(13)62343-0","article-title":"Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials","volume":"383","author":"Ruff","year":"2014","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.thromres.2024.04.009_bb0260","doi-asserted-by":"crossref","first-page":"554","DOI":"10.3390\/jcm8040554","article-title":"Effectiveness and safety of direct oral anticoagulants versus vitamin K antagonists for people aged 75 years and over with atrial fibrillation: a systematic review and meta-analyses of observational studies","volume":"8","author":"Mitchell","year":"2019","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.thromres.2024.04.009_bb0265","doi-asserted-by":"crossref","first-page":"132","DOI":"10.3389\/fcvm.2020.00132","article-title":"Direct oral anticoagulants vs. vitamin-K antagonists in the elderly with atrial fibrillation: a systematic review comparing benefits and harms between observational studies and randomized controlled trials","volume":"7","author":"Shen","year":"2020","journal-title":"Frontiers in Cardiovascular Medicine."},{"issue":"FI1","key":"10.1016\/j.thromres.2024.04.009_bb0270","doi-asserted-by":"crossref","first-page":"f20","DOI":"10.1093\/ehjcvp\/pvz073","article-title":"Safety and efficacy of non-vitamin K antagonist oral anticoagulants in elderly patients with atrial fibrillation: systematic review and meta-analysis of 22 studies and 440281 patients","volume":"7","author":"Silverio","year":"2019","journal-title":"European Heart Journal - Cardiovascular Pharmacotherapy."},{"key":"10.1016\/j.thromres.2024.04.009_bb0275","first-page":"1","article-title":"Safety outcomes of direct oral anticoagulants in older adults with atrial fibrillation: a systematic review and meta-analysis of (subgroup analyses from) randomized controlled trials","author":"Doni","year":"2023","journal-title":"GeroScience"},{"key":"10.1016\/j.thromres.2024.04.009_bb0280","first-page":"e1","article-title":"Clinical and safety outcomes of oral antithrombotics for stroke prevention in atrial fibrillation: a systematic review and network meta-analysis","volume":"16(12):1103","author":"Lin","year":"2015","journal-title":"J. Am. Med. Dir. Assoc."},{"key":"10.1016\/j.thromres.2024.04.009_bb0285","article-title":"Direct oral anticoagulants in the elderly: systematic review and meta-analysis of evidence, current and future directions","volume":"146(3940):w14356-w","author":"Sadlon","year":"2016","journal-title":"Swiss Med. Wkly."},{"issue":"12","key":"10.1016\/j.thromres.2024.04.009_bb0290","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.1016\/j.amjcard.2019.02.060","article-title":"Meta-analysis of direct-acting oral anticoagulants compared with warfarin in patients >75 years of age","volume":"123","author":"Malik","year":"2019","journal-title":"Am. J. Cardiol."},{"issue":"8","key":"10.1016\/j.thromres.2024.04.009_bb0295","doi-asserted-by":"crossref","DOI":"10.1016\/j.jamda.2023.05.010","article-title":"Efficacy and safety of oral anticoagulants in older adult patients with atrial fibrillation: pairwise and network meta-analyses","volume":"24","author":"Wang","year":"2023","journal-title":"J. Am. Med. Dir. Assoc."},{"key":"10.1016\/j.thromres.2024.04.009_bb0300","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2023.1125576","article-title":"Long-term comparative effectiveness and safety of dabigatran, rivaroxaban, apixaban and edoxaban in patients with atrial fibrillation: a nationwide cohort study","volume":"14","author":"Grymonprez","year":"2023","journal-title":"Front. Pharmacol."},{"issue":"18","key":"10.1016\/j.thromres.2024.04.009_bb0305","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1056\/NEJMoa2012883","article-title":"Low-dose edoxaban in very elderly patients with atrial fibrillation","volume":"383","author":"Okumura","year":"2020","journal-title":"New England Journal of Medicine."},{"key":"10.1016\/j.thromres.2024.04.009_bb0310","article-title":"Outcomes and safety of very-low-dose edoxaban in frail patients with atrial fibrillation in the ELDERCARE-AF randomized clinical trial","volume":"5(8):e2228500-e","author":"Akashi","year":"2022","journal-title":"JAMA Netw. Open"},{"key":"10.1016\/j.thromres.2024.04.009_bb0315","article-title":"Optimal stroke preventive strategy for patients aged 80 years or older with atrial fibrillation: a systematic review with traditional and network meta-analysis","volume":"51(12):afac292","author":"Lee","year":"2022","journal-title":"Age Ageing"},{"issue":"4","key":"10.1016\/j.thromres.2024.04.009_bb0320","first-page":"279","article-title":"Safety of switching from a vitamin K antagonist to a non-vitamin K antagonist oral anticoagulant in frail older patients with atrial fibrillation: results of the FRAIL-AF randomized controlled trial","volume":"149","author":"Joosten","year":"2023","journal-title":"Circulation"},{"issue":"7","key":"10.1016\/j.thromres.2024.04.009_bb0325","doi-asserted-by":"crossref","first-page":"2052","DOI":"10.1111\/jgs.18372","article-title":"American geriatrics society 2023 updated AGS beers criteria\u00ae for potentially inappropriate medication use in older adults","volume":"71","author":"AGS","year":"2023","journal-title":"J. Am. Geriatr. Soc."},{"issue":"12","key":"10.1016\/j.thromres.2024.04.009_bb0330","first-page":"1968","article-title":"Direct oral anticoagulants compared with vitamin K antagonists for acute venous thromboembolism: evidence from phase 3 trials","volume":"124","author":"Van Es","year":"2014","journal-title":"Blood, The Journal of the American Society of Hematology."},{"issue":"6","key":"10.1016\/j.thromres.2024.04.009_bb0335","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1111\/joim.13712","article-title":"Association of type of oral anticoagulation with risk of bleeding in 45,114 patients with venous thromboembolism during initial and extended treatment - a nationwide register-based study","volume":"294","author":"Glise Sandblad","year":"2023","journal-title":"J. Intern. Med."},{"issue":"1","key":"10.1016\/j.thromres.2024.04.009_bb0340","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.amjmed.2022.08.033","article-title":"Effectiveness and safety of direct oral anticoagulants among octogenarians with venous thromboembolism: an international multidatabase cohort study","volume":"136","author":"Douros","year":"2023","journal-title":"Am. J. Med."},{"issue":"11","key":"10.1016\/j.thromres.2024.04.009_bb0345","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1001\/jama.2022.1920","article-title":"Association of type of oral anticoagulant dispensed with adverse clinical outcomes in patients extending anticoagulation therapy beyond 90 days after hospitalization for venous thromboembolism","volume":"327","author":"Pawar","year":"2022","journal-title":"JAMA"},{"issue":"5","key":"10.1016\/j.thromres.2024.04.009_bb0350","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1159\/000528606","article-title":"Comparative safety and effectiveness of direct oral anticoagulants and warfarin during chemotherapy in cancer patients with venous thromboembolismaged 75 years or older: a nationwide inpatient database study","volume":"69","author":"Iwai","year":"2023","journal-title":"Gerontology"},{"issue":"17","key":"10.1016\/j.thromres.2024.04.009_bb0355","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1056\/NEJMoa1915103","article-title":"Apixaban for the treatment of venous thromboembolism associated with cancer","volume":"382","author":"Agnelli","year":"2020","journal-title":"N. Engl. J. Med."},{"issue":"7","key":"10.1016\/j.thromres.2024.04.009_bb0360","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1056\/NEJMoa1711948","article-title":"Edoxaban for the treatment of cancer-associated venous thromboembolism","volume":"378","author":"Raskob","year":"2017","journal-title":"New England Journal of Medicine."},{"issue":"6","key":"10.1016\/j.thromres.2024.04.009_bb0365","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.amjmed.2005.02.018","article-title":"Oral anticoagulation strategies after a first idiopathic venous thromboembolic event","volume":"118","author":"Aujesky","year":"2005","journal-title":"American Journal of Medicine."},{"issue":"8","key":"10.1016\/j.thromres.2024.04.009_bb0370","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1016\/j.amjmed.2012.01.033","article-title":"Risk of falls and major bleeds in patients on oral anticoagulation therapy","volume":"125","author":"Donz\u00e9","year":"2012","journal-title":"American Journal of Medicine."},{"issue":"11","key":"10.1016\/j.thromres.2024.04.009_bb0375","doi-asserted-by":"crossref","first-page":"1512","DOI":"10.1055\/s-0041-1726345","article-title":"Comparison of bleeding risk scores in elderly patients receiving extended anticoagulation with vitamin K antagonists for venous thromboembolism","volume":"121","author":"Frei","year":"2021","journal-title":"Thromb. Haemost."},{"key":"10.1016\/j.thromres.2024.04.009_bb0380","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.thromres.2017.05.015","article-title":"Venous thromboembolism in the elderly: a narrative review","volume":"155","author":"Tritschler","year":"2017","journal-title":"Thromb. Res."},{"issue":"4","key":"10.1016\/j.thromres.2024.04.009_bb0385","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1093\/eurheartj\/ehz405","volume":"41","author":"Konstantinides","year":"2019","journal-title":"Eur. Heart J."},{"issue":"2","key":"10.1016\/j.thromres.2024.04.009_bb0390","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.chest.2015.11.026","article-title":"Antithrombotic therapy for VTE disease: CHEST guideline and expert panel report","volume":"149","author":"Kearon","year":"2016","journal-title":"Chest"},{"issue":"1","key":"10.1016\/j.thromres.2024.04.009_bb0395","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1186\/1471-2296-14-86","article-title":"Frailty prevalence and slow walking speed in persons age 65 and older: implications for primary care","volume":"14","author":"Castell","year":"2013","journal-title":"BMC Fam. Pract."},{"issue":"3","key":"10.1016\/j.thromres.2024.04.009_bb0400","doi-asserted-by":"crossref","first-page":"M146","DOI":"10.1093\/gerona\/56.3.M146","article-title":"Frailty in older adults: evidence for a phenotype","volume":"56","author":"Fried","year":"2001","journal-title":"J. Gerontol. A Biol. Sci. Med. Sci."},{"issue":"3","key":"10.1016\/j.thromres.2024.04.009_bb0405","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1093\/ageing\/afaa265","article-title":"Atrial fibrillation and oral anticoagulation in older people with frailty: a nationwide primary care electronic health records cohort study","volume":"50","author":"Wilkinson","year":"2021","journal-title":"Age Ageing"},{"issue":"12","key":"10.1016\/j.thromres.2024.04.009_bb0410","doi-asserted-by":"crossref","first-page":"3503","DOI":"10.1111\/jgs.18001","article-title":"Frailty phenotype as a predictor of bleeding and mortality in ambulatory patients receiving direct oral anticoagulants","volume":"70","author":"Candeloro","year":"2022","journal-title":"J. Am. Geriatr. Soc."},{"issue":"12","key":"10.1016\/j.thromres.2024.04.009_bb0415","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.119.015656","article-title":"Long-term association of venous thromboembolismwith frailty, physical functioning, and quality of life: the atherosclerosis tisk in communities study","volume":"9","author":"Lutsey","year":"2020","journal-title":"J. Am. Heart Assoc."},{"issue":"1","key":"10.1016\/j.thromres.2024.04.009_bb0420","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1186\/s12916-020-01870-w","article-title":"Clinical outcomes in patients with atrial fibrillation and frailty: insights from the ENGAGE AF-TIMI 48 trial","volume":"18","author":"Wilkinson","year":"2020","journal-title":"BMC Med."},{"key":"10.1016\/j.thromres.2024.04.009_bb0425","doi-asserted-by":"crossref","DOI":"10.1016\/j.arr.2022.101652","article-title":"Frailty prevalence and impact on outcomes in patients with atrial fibrillation: a systematic review and meta-analysis of 1,187,000 patients","volume":"79","author":"Proietti","year":"2022","journal-title":"Ageing Res. Rev."},{"issue":"2","key":"10.1016\/j.thromres.2024.04.009_bb0430","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1182\/bloodadvances.2022007263","article-title":"Incidence and clinical impact of bleeding events in older patients with acute venous thromboembolism","volume":"7","author":"Ferrazzini","year":"2023","journal-title":"Blood Adv."},{"issue":"2","key":"10.1016\/j.thromres.2024.04.009_bb0435","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1093\/ageing\/afn293","article-title":"The impact of frailty on the utilisation of antithrombotic therapy in older patients with atrial fibrillation","volume":"38","author":"Perera","year":"2009","journal-title":"Age Ageing"},{"issue":"1","key":"10.1016\/j.thromres.2024.04.009_bb0440","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1093\/ehjqcco\/qcad019","article-title":"Impact of frailty on the effectiveness and safety of non-vitamin K antagonist oral anticoagulants (NOACs) in patients with atrial fibrillation: a nationwide cohort study","volume":"10","author":"Grymonprez","year":"2023","journal-title":"European Heart Journal - Quality of Care and Clinical Outcomes"},{"issue":"9","key":"10.1016\/j.thromres.2024.04.009_bb0445","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.7326\/M20-7141","article-title":"Frailty and clinical outcomes of direct oral anticoagulants versus warfarin in older adults with atrial fibrillation: a cohort study","volume":"174","author":"Kim","year":"2021","journal-title":"Ann. Intern. Med."},{"issue":"8","key":"10.1016\/j.thromres.2024.04.009_bb0450","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.118.008643","article-title":"Effectiveness and safety of apixaban, dabigatran, and rivaroxaban versus warfarin in frail patients with nonvalvular atrial fibrillation","volume":"7","author":"Martinez","year":"2018","journal-title":"J. Am. Heart Assoc."},{"issue":"8","key":"10.1016\/j.thromres.2024.04.009_bb0455","doi-asserted-by":"crossref","DOI":"10.1016\/j.amjmed.2018.02.015","article-title":"Effectiveness and safety of rivaroxaban versus warfarin in frail patients with venous thromboembolism","volume":"131","author":"Coleman","year":"2018","journal-title":"American Journal of Medicine."},{"key":"10.1016\/j.thromres.2024.04.009_bb0460","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.thromres.2020.11.039","article-title":"Safety and effectiveness of apixaban compared with warfarin among clinically-relevant subgroups of venous thromboembolism patients in the United States medicare population","volume":"198","author":"Guo","year":"2021","journal-title":"Thromb. Res."},{"key":"10.1016\/j.thromres.2024.04.009_bb0465","article-title":"Frailty, home time, and health care costs in older adults with atrial fibrillation receiving oral anticoagulants","volume":"6(11):e2342264-e","author":"Lin","year":"2023","journal-title":"JAMA Netw. Open"},{"key":"10.1016\/j.thromres.2024.04.009_bb0470","article-title":"Impact of multimorbidity and polypharmacy on clinical outcomes of elderly chinese patients with atrial fibrillation. Journal of","volume":"11(5):1370","author":"Kotalczyk","year":"2022","journal-title":"Clin. Med."},{"key":"10.1016\/j.thromres.2024.04.009_bb0475","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.thromres.2019.02.017","article-title":"Anticoagulation quality and clinical outcomes in multimorbid elderly patients with acute venous thromboembolism","volume":"177","author":"Lange","year":"2019","journal-title":"Thromb. Res."},{"issue":"6","key":"10.1016\/j.thromres.2024.04.009_bb0480","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1016\/j.hrthm.2021.02.018","article-title":"Oral anticoagulants in extremely-high-risk, very elderly (>90 years) patients with atrial fibrillation","volume":"18","author":"Chao","year":"2021","journal-title":"Heart Rhythm"},{"issue":"14","key":"10.1016\/j.thromres.2024.04.009_bb0485","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1093\/eurheartj\/ehac776","article-title":"Recurrent venous thromboembolism and bleeding with extended anticoagulation: the VTE-PREDICT risk score","volume":"44","author":"De Winter","year":"2023","journal-title":"Eur. Heart J."},{"issue":"5","key":"10.1016\/j.thromres.2024.04.009_bb0490","article-title":"How to predict recurrent venous thromboembolism and bleeding? A review of recent advances and their implications. Polish","volume":"133","author":"Burggraaf","year":"2023","journal-title":"Arch. Intern. Med."},{"key":"10.1016\/j.thromres.2024.04.009_bb0495","doi-asserted-by":"crossref","DOI":"10.1016\/j.exger.2021.111482","article-title":"Relationship between multimorbidity and outcomes in atrial fibrillation","volume":"153","author":"Proietti","year":"2021","journal-title":"Exp. Gerontol."},{"issue":"6","key":"10.1016\/j.thromres.2024.04.009_bb0500","doi-asserted-by":"crossref","first-page":"3166","DOI":"10.1007\/s12325-021-01724-8","article-title":"Use of non-vitamin K antagonist oral anticoagulants among patients with nonvalvular atrial fibrillation and multimorbidity","volume":"38","author":"Deitelzweig","year":"2021","journal-title":"Adv. Ther."},{"issue":"3","key":"10.1016\/j.thromres.2024.04.009_bb0505","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1007\/s12325-022-02387-9","article-title":"Effectiveness and safety of direct oral anticoagulants among patients with non-valvular atrial fibrillation and multimorbidity","volume":"40","author":"Dhamane","year":"2023","journal-title":"Adv. Ther."},{"issue":"1","key":"10.1016\/j.thromres.2024.04.009_bb0510","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1186\/s12877-017-0621-2","article-title":"What is polypharmacy? A systematic review of definitions","volume":"17","author":"Masnoon","year":"2017","journal-title":"BMC Geriatr."},{"key":"10.1016\/j.thromres.2024.04.009_bb0515","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/s11606-014-2993-8","article-title":"Polypharmacy is associated with an increased risk of bleeding in elderly patients with venous thromboembolism","volume":"30","author":"Leiss","year":"2015","journal-title":"J. Gen. Intern. Med."},{"key":"10.1016\/j.thromres.2024.04.009_bb0520","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2022.114064","article-title":"Polypharmacy and adverse events in atrial fibrillation: main cause or reflection of multimorbidity?","volume":"158","author":"Mart\u00ednez-Montesinos","year":"2023","journal-title":"Biomed. Pharmacother."},{"issue":"3","key":"10.1016\/j.thromres.2024.04.009_bb0525","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1111\/jgs.15712","article-title":"Relevance of polypharmacy for clinical outcome in patients receiving vitamin K antagonists","volume":"67","author":"Eggebrecht","year":"2019","journal-title":"J. Am. Geriatr. Soc."},{"issue":"02","key":"10.1016\/j.thromres.2024.04.009_bb0530","first-page":"135","article-title":"The impact of polypharmacy on the effectiveness and safety of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation","volume":"124","author":"Grymonprez","year":"2023","journal-title":"Thromb. Haemost."},{"key":"10.1016\/j.thromres.2024.04.009_bb0535","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.thromres.2020.07.054","article-title":"The increased risk of bleeding due to drug-drug interactions in patients administered direct oral anticoagulants","volume":"195","author":"Lee","year":"2020","journal-title":"Thromb. Res."},{"issue":"21","key":"10.1016\/j.thromres.2024.04.009_bb0540","first-page":"2230","article-title":"Drug-drug interactions in an era of multiple anticoagulants: a focus on clinically relevant drug interactions","volume":"132","author":"Vazquez","year":"2018","journal-title":"Blood, The Journal of the American Society of Hematology."},{"issue":"5","key":"10.1016\/j.thromres.2024.04.009_bb0545","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1097\/CRD.0000000000000088","article-title":"Non-vitamin K antagonist oral anticoagulants and antiplatelet therapy for stroke prevention in patients with atrial fibrillation: a meta-analysis of randomized controlled trials","volume":"24","author":"Kumar","year":"2016","journal-title":"Cardiol. Rev."},{"issue":"7","key":"10.1016\/j.thromres.2024.04.009_bb0550","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1161\/CIRCULATIONAHA.113.002927","article-title":"Use and associated risks of concomitant aspirin therapy with oral anticoagulation in patients with atrial fibrillation: insights from the outcomes registry for better informed treatment of atrial fibrillation (ORBIT-AF) registry","volume":"128","author":"Steinberg","year":"2013","journal-title":"Circulation"},{"issue":"7","key":"10.1016\/j.thromres.2024.04.009_bb0555","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1111\/jth.14807","article-title":"Impact of concomitant antiplatelet therapy on the efficacy and safety of direct oral anticoagulants for acute venous thromboembolism: systematic review and meta-analysis","volume":"18","author":"Valeriani","year":"2020","journal-title":"J. Thromb. Haemost."},{"key":"10.1016\/j.thromres.2024.04.009_bb0560","article-title":"Effect of oral anticoagulants in atrial fibrillation patients with polypharmacy: a meta-analysis","author":"Zheng","year":"2023","journal-title":"Thromb. Haemost."},{"key":"10.1016\/j.thromres.2024.04.009_bb0565","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.thromres.2017.12.005","article-title":"Impact of age, comorbidity, and polypharmacy on the efficacy and safety of edoxaban for the treatment of venous thromboembolism: an analysis of the randomized, double-blind hokusai-VTE trial","volume":"162","author":"Vanassche","year":"2018","journal-title":"Thromb. Res."},{"issue":"6","key":"10.1016\/j.thromres.2024.04.009_bb0570","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1111\/jth.15692","article-title":"Effect of polypharmacy on bleeding with rivaroxaban versus vitamin K antagonist for treatment of venous thromboembolism","volume":"20","author":"Bistervels","year":"2022","journal-title":"J. Thromb. Haemost."},{"issue":"4","key":"10.1016\/j.thromres.2024.04.009_bb0575","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1111\/joim.12236","article-title":"Risk of falls and bleeding in elderly patients with acute venous thromboembolism","volume":"276","author":"K\u00e4mpfen","year":"2014","journal-title":"J. Intern. Med."},{"issue":"2","key":"10.1016\/j.thromres.2024.04.009_bb0580","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1111\/jgs.16822","article-title":"Geriatric syndromes and atrial fibrillation: prevalence and association with anticoagulant use in a national cohort of older americans","volume":"69","author":"Shah","year":"2021","journal-title":"J. Am. Geriatr. Soc."},{"issue":"4","key":"10.1016\/j.thromres.2024.04.009_bb0585","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1016\/j.mayocp.2019.09.029","article-title":"Atrial fibrillation is associated with syncope and falls in older adults: a systematic review and meta-analysis","volume":"95","author":"Malik","year":"2020","journal-title":"Mayo Clin. Proc."},{"issue":"6","key":"10.1016\/j.thromres.2024.04.009_bb0590","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1093\/ageing\/afr097","article-title":"Attitudes of physicians regarding anticoagulation for atrial fibrillation: a systematic review","volume":"40","author":"Pugh","year":"2011","journal-title":"Age Ageing"},{"issue":"7","key":"10.1016\/j.thromres.2024.04.009_bb0595","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1161\/CIRCULATIONAHA.110.007864","article-title":"Bleeding risk in very old patients on vitamin K antagonist treatment: results of a prospective collaborative study on elderly patients followed by italian centres for anticoagulation","volume":"124","author":"Poli","year":"2011","journal-title":"Circulation"},{"issue":"1","key":"10.1016\/j.thromres.2024.04.009_bb0600","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1111\/bjh.15509","article-title":"Incidence of intracranial bleeding in anticoagulated patients with minor head injury: a systematic review and meta-analysis of prospective studies","volume":"183","author":"Minhas","year":"2018","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.thromres.2024.04.009_bb0605","doi-asserted-by":"crossref","first-page":"e339","DOI":"10.1016\/j.wneu.2017.10.173","article-title":"Are antiplatelet and anticoagulants drugs a risk factor for bleeding in mild traumatic brain injury?","volume":"110","author":"Uccella","year":"2018","journal-title":"World Neurosurg."},{"issue":"5","key":"10.1016\/j.thromres.2024.04.009_bb0610","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1111\/jgs.16400","article-title":"Prevalence and severity of traumatic intracranial hemorrhage in older adults with low-energy falls","volume":"68","author":"Lampart","year":"2020","journal-title":"J. Am. Geriatr. Soc."},{"issue":"6","key":"10.1016\/j.thromres.2024.04.009_bb0615","doi-asserted-by":"crossref","first-page":"1656","DOI":"10.1161\/STROKEAHA.122.041628","article-title":"Clinical outcomes of anticoagulated patients with atrial fibrillation after falls or head injury: insights from RE-LY","volume":"54","author":"Caldeira","year":"2023","journal-title":"Stroke"},{"issue":"1","key":"10.1016\/j.thromres.2024.04.009_bb0620","doi-asserted-by":"crossref","first-page":"35","DOI":"10.3949\/ccjm.84a.16016","article-title":"Fall risk and anticoagulation for atrial fibrillation in the elderly: a delicate balance","volume":"84","author":"Hagerty","year":"2017","journal-title":"Cleve. Clin. J. Med."},{"issue":"1","key":"10.1016\/j.thromres.2024.04.009_bb0625","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1161\/STROKEAHA.114.007199","article-title":"Stroke and major bleeding risk in elderly patients aged\u2265 75 years with atrial fibrillation: the loire valley atrial fibrillation project","volume":"46","author":"Lip","year":"2015","journal-title":"Stroke"},{"issue":"2","key":"10.1016\/j.thromres.2024.04.009_bb0630","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.jacc.2021.10.037","article-title":"Management of atrial fibrillation in patients 75 years and older: JACC state-of-the-art review","volume":"79","author":"Volgman","year":"2022","journal-title":"J. Am. Coll. Cardiol."},{"issue":"11","key":"10.1016\/j.thromres.2024.04.009_bb0635","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1007\/s40264-022-01231-x","article-title":"Efficacy and safety of anticoagulants in patients with atrial fibrillation and history of falls or risk of falls: a systematic review and multilevel meta-analysis","volume":"45","author":"Galvain","year":"2022","journal-title":"Drug Saf."},{"key":"10.1016\/j.thromres.2024.04.009_bb0640","article-title":"Clinical outcomes in patients with atrial fibrillation and a history of falls using non-vitamin K antagonist oral anticoagulants: a nationwide cohort study","volume":"47","author":"Grymonprez","year":"2023","journal-title":"International Journal of Cardiology: Heart & Vasculature."},{"issue":"1","key":"10.1016\/j.thromres.2024.04.009_bb0645","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13049-021-00866-6","article-title":"Falls in ED patients: do elderly patients on direct oral anticoagulants bleed less than those on vitamin K antagonists? Scandinavian journal of trauma","volume":"29","author":"M\u00fcller","year":"2021","journal-title":"Resuscitation and Emergency Medicine."},{"issue":"5","key":"10.1016\/j.thromres.2024.04.009_bb0650","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1161\/CIRCULATIONAHA.121.055018","article-title":"Atrial fibrillation and dementia: a report from the AF-SCREEN international collaboration","volume":"145","author":"Rivard","year":"2022","journal-title":"Circulation"},{"issue":"12","key":"10.1016\/j.thromres.2024.04.009_bb0655","doi-asserted-by":"crossref","first-page":"e1309","DOI":"10.1212\/WNL.0000000000206748","article-title":"Oral anticoagulants and the risk of dementia in patients with nonvalvular atrial fibrillation: a population-based cohort study","volume":"100","author":"Rahman","year":"2023","journal-title":"Neurology"},{"issue":"3","key":"10.1016\/j.thromres.2024.04.009_bb0660","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1378\/chest.12-1119","article-title":"Gaps in monitoring during oral anticoagulation: insights into care transitions, monitoring barriers, and medication nonadherence","volume":"143","author":"Rose","year":"2013","journal-title":"Chest"},{"key":"10.1016\/j.thromres.2024.04.009_bb0665","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2022.994085","article-title":"Adherence and persistence to oral anticoagulants in patients with atrial fibrillation: a belgian nationwide cohort study","volume":"9","author":"Grymonprez","year":"2022","journal-title":"Frontiers in Cardiovascular Medicine."},{"issue":"3","key":"10.1016\/j.thromres.2024.04.009_bb0670","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1007\/s40801-022-00311-9","article-title":"Impact of medication adherence on the association between oral anticoagulant use and risk of dementia: a retrospective cohort study using the japanese claims database","volume":"9","author":"Komatsu","year":"2022","journal-title":"Drugs-Real World Outcomes."},{"issue":"3","key":"10.1016\/j.thromres.2024.04.009_bb0675","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1111\/bjh.16383","article-title":"Prediction of significant bleeding during vitamin K antagonist treatment for venous thromboembolism in outpatients","volume":"189","author":"Martinez","year":"2020","journal-title":"Br. J. Haematol."},{"issue":"2","key":"10.1016\/j.thromres.2024.04.009_bb0680","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.thromres.2012.02.006","article-title":"Venous thromboembolism in immobilized patients with dementia. Findings from the RIETE registry","volume":"130","author":"Nu\u00f1ez","year":"2012","journal-title":"Thromb. Res."},{"key":"10.1016\/j.thromres.2024.04.009_bb0685","article-title":"Comparative effectiveness and safety of oral anticoagulants by dementia status in older patients with atrial fibrillation","volume":"6(3):e234086-e","author":"Lin","year":"2023","journal-title":"JAMA Netw. Open"},{"key":"10.1016\/j.thromres.2024.04.009_bb0690","article-title":"Clinical benefits of oral anticoagulants in atrial fibrillation patients with dementia: a systematic review and meta-analysis","volume":"10","author":"Wang","year":"2023","journal-title":"Frontiers in Cardiovascular Medicine."},{"key":"10.1016\/j.thromres.2024.04.009_bb0695","article-title":"Comparing the risk of dementia in subjects with atrial fibrillation using non-vitamin K antagonist oral anticoagulants versus vitamin K antagonists: a belgian nationwide cohort study","volume":"52(3):afad038","author":"Grymonprez","year":"2023","journal-title":"Age Ageing"},{"issue":"6","key":"10.1016\/j.thromres.2024.04.009_bb0700","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1093\/europace\/euaa017","article-title":"Impact of malnutrition in the embolic\u2013haemorrhagic trade-off of elderly patients with atrial fibrillation","volume":"22","author":"Raposeiras-Roub\u00edn","year":"2020","journal-title":"EP Europace."},{"issue":"2","key":"10.1016\/j.thromres.2024.04.009_bb0705","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.jjcc.2020.10.008","article-title":"Relationship between the nutritional status and safety and efficacy outcomes in atrial fibrillation patients aged 80 years and over receiving oral anticoagulants","volume":"77","author":"Shinohara","year":"2021","journal-title":"J. Cardiol."},{"issue":"5","key":"10.1016\/j.thromres.2024.04.009_bb0710","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1016\/j.jtha.2023.02.015","article-title":"Outcomes of venous thromboembolism care: future directions","volume":"21","author":"De Jong","year":"2023","journal-title":"J. Thromb. Haemost."},{"key":"10.1016\/j.thromres.2024.04.009_bb0715","first-page":"e1","article-title":"ACC\/AHA\/ACCP\/HRS guideline for the diagnosis and management of atrial fibrillation: a report of the american college of cardiology\/american heart association joint committee on clinical practice guidelines","volume":"149","author":"Members","year":"2023","journal-title":"J. Am. Coll. Cardiol."},{"issue":"5","key":"10.1016\/j.thromres.2024.04.009_bb0720","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1016\/j.chest.2018.07.040","article-title":"Antithrombotic therapy for atrial fibrillation: CHEST guideline and expert panel report","volume":"154","author":"Lip","year":"2018","journal-title":"Chest"},{"issue":"12","key":"10.1016\/j.thromres.2024.04.009_bb0725","doi-asserted-by":"crossref","first-page":"1847","DOI":"10.1016\/j.cjca.2020.09.001","article-title":"The 2020 Canadian cardiovascular society\/Canadian geart rhythm cociety comprehensive guidelines for the management of atrial fibrillation","volume":"36","author":"Andrade","year":"2020","journal-title":"Can. J. Cardiol."},{"key":"10.1016\/j.thromres.2024.04.009_bb0730","unstructured":"NICE. Atrial fibrillation: diagnosis and management 2021 [Available from: https:\/\/www.nice.org.uk\/guidance\/ng196."},{"issue":"16","key":"10.1016\/j.thromres.2024.04.009_bb0735","doi-asserted-by":"crossref","first-page":"3063","DOI":"10.1200\/JCO.23.00294","article-title":"Venous thromboembolism prophylaxis and treatment in patients with cancer: ASCO guideline update","volume":"41","author":"Key","year":"2023","journal-title":"J. Clin. Oncol."},{"issue":"4","key":"10.1016\/j.thromres.2024.04.009_bb0740","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1182\/bloodadvances.2020003442","article-title":"American society of hematology 2021 guidelines for management of venous thromboembolism: prevention and treatment in patients with cancer","volume":"5","author":"Lyman","year":"2021","journal-title":"Blood Adv."},{"issue":"5","key":"10.1016\/j.thromres.2024.04.009_bb0745","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1016\/j.annonc.2022.12.014","article-title":"Venous thromboembolism in cancer patients: ESMO clinical practice guideline","volume":"34","author":"Falanga","year":"2023","journal-title":"Ann. Oncol."},{"issue":"1","key":"10.1016\/j.thromres.2024.04.009_bb0750","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.ejvs.2020.09.023","article-title":"European society for vascular surgery (ESVS) 2021 clinical practice guidelines on the management of venous thrombosis","volume":"61","author":"Kakkos","year":"2021","journal-title":"Eur. J. Vasc. Endovasc. Surg."},{"issue":"7","key":"10.1016\/j.thromres.2024.04.009_bb0755","doi-asserted-by":"crossref","first-page":"e334","DOI":"10.1016\/S1470-2045(22)00160-7","article-title":"2022 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer, including patients with COVID-19","volume":"23","author":"Farge","year":"2022","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.thromres.2024.04.009_bb0760","unstructured":"NICE. Venous thromboembolic diseases: diagnosis, management and thrombophilia testing 2023 [Available from: https:\/\/www.nice.org.uk\/guidance\/ng158."},{"issue":"5","key":"10.1016\/j.thromres.2024.04.009_bb0765","doi-asserted-by":"crossref","first-page":"227","DOI":"10.5694\/mja2.50004","article-title":"New guidelines from the thrombosis and haemostasis society of Australia and New Zealand for the diagnosis and management of venous thromboembolism","volume":"210","author":"Tran","year":"2019","journal-title":"Med. J. Aust."}],"container-title":["Thrombosis Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049384824001221?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049384824001221?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,5,18]],"date-time":"2024-05-18T04:40:10Z","timestamp":1716007210000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0049384824001221"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6]]},"references-count":153,"alternative-id":["S0049384824001221"],"URL":"https:\/\/doi.org\/10.1016\/j.thromres.2024.04.009","relation":{},"ISSN":["0049-3848"],"issn-type":[{"value":"0049-3848","type":"print"}],"subject":[],"published":{"date-parts":[[2024,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Oral anticoagulant therapy in older adults","name":"articletitle","label":"Article Title"},{"value":"Thrombosis Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.thromres.2024.04.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}